EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 147 filers reported holding EAGLE PHARMACEUTICALS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $5,450 | -38.8% | 1,040 | -38.9% | 0.00% | – |
Q4 2023 | $8,907 | -75.3% | 1,703 | -25.4% | 0.00% | – |
Q3 2023 | $36,003 | -86.6% | 2,283 | -83.5% | 0.00% | – |
Q2 2023 | $268,272 | -32.9% | 13,800 | -2.1% | 0.00% | -100.0% |
Q1 2023 | $399,875 | -5.4% | 14,095 | -2.6% | 0.00% | 0.0% |
Q4 2022 | $422,841 | +11.9% | 14,466 | +1.1% | 0.00% | 0.0% |
Q3 2022 | $378,000 | -41.4% | 14,313 | -1.3% | 0.00% | 0.0% |
Q2 2022 | $645,000 | -9.7% | 14,506 | +0.5% | 0.00% | 0.0% |
Q1 2022 | $714,000 | -10.9% | 14,433 | -8.3% | 0.00% | 0.0% |
Q4 2021 | $801,000 | -7.4% | 15,738 | +1.5% | 0.00% | 0.0% |
Q3 2021 | $865,000 | +25.4% | 15,504 | -3.9% | 0.00% | 0.0% |
Q2 2021 | $690,000 | +5.3% | 16,131 | +2.7% | 0.00% | 0.0% |
Q1 2021 | $655,000 | -10.4% | 15,702 | 0.0% | 0.00% | 0.0% |
Q4 2020 | $731,000 | +4.7% | 15,702 | -4.5% | 0.00% | 0.0% |
Q3 2020 | $698,000 | -11.5% | 16,440 | 0.0% | 0.00% | 0.0% |
Q2 2020 | $789,000 | +21.9% | 16,440 | +16.9% | 0.00% | 0.0% |
Q1 2020 | $647,000 | -22.5% | 14,068 | +1.2% | 0.00% | 0.0% |
Q4 2019 | $835,000 | +3.3% | 13,906 | -2.7% | 0.00% | -50.0% |
Q3 2019 | $808,000 | +1.5% | 14,288 | 0.0% | 0.00% | 0.0% |
Q2 2019 | $796,000 | -2.6% | 14,288 | -11.7% | 0.00% | 0.0% |
Q1 2019 | $817,000 | +21.9% | 16,178 | -2.7% | 0.00% | 0.0% |
Q4 2018 | $670,000 | -40.2% | 16,624 | +2.8% | 0.00% | 0.0% |
Q3 2018 | $1,121,000 | -7.0% | 16,165 | +1.5% | 0.00% | -33.3% |
Q2 2018 | $1,205,000 | +87.7% | 15,933 | +30.8% | 0.00% | +200.0% |
Q1 2018 | $642,000 | -7.1% | 12,183 | -5.8% | 0.00% | 0.0% |
Q4 2017 | $691,000 | -11.6% | 12,933 | -1.4% | 0.00% | -50.0% |
Q3 2017 | $782,000 | -31.9% | 13,114 | -10.0% | 0.00% | 0.0% |
Q2 2017 | $1,149,000 | -20.7% | 14,565 | -16.6% | 0.00% | -33.3% |
Q1 2017 | $1,449,000 | 0.0% | 17,465 | -4.4% | 0.00% | 0.0% |
Q4 2016 | $1,449,000 | +10.3% | 18,265 | -2.7% | 0.00% | 0.0% |
Q3 2016 | $1,314,000 | +82.5% | 18,765 | +1.1% | 0.00% | +50.0% |
Q2 2016 | $720,000 | -2.2% | 18,565 | +2.1% | 0.00% | 0.0% |
Q1 2016 | $736,000 | -47.7% | 18,180 | +14.6% | 0.00% | -33.3% |
Q4 2015 | $1,407,000 | +21.3% | 15,870 | +1.3% | 0.00% | 0.0% |
Q3 2015 | $1,160,000 | -8.4% | 15,670 | 0.0% | 0.00% | 0.0% |
Q2 2015 | $1,267,000 | +1524.4% | 15,670 | +156.9% | 0.00% | – |
Q1 2014 | $78,000 | – | 6,100 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Hudson Executive Capital LP | 1,323,794 | $79,534,000 | 3.54% |
Park West Asset Management LLC | 1,171,880 | $70,406,000 | 2.96% |
Matarin Capital Management, LLC | 170,008 | $10,214,000 | 0.98% |
Smith, Graham & Co., Investment Advisors, LP | 140,014 | $8,412,000 | 0.82% |
Capital Impact Advisors, LLC | 33,725 | $2,026,000 | 0.71% |
U S GLOBAL INVESTORS INC | 18,800 | $1,130,000 | 0.51% |
CHARTWELL INVESTMENT PARTNERS, LLC | 187,989 | $11,294,000 | 0.37% |
Stanley-Laman Group, Ltd. | 24,000 | $1,442,000 | 0.34% |
GLOBEFLEX CAPITAL L P | 18,751 | $1,127,000 | 0.21% |
Foundry Partners, LLC | 70,357 | $4,227,000 | 0.16% |